2013 AACC MEETING, HOUSTON, TX

L. Chang1, P. Patel1, L. Song1, Y. Chen1, D. Hanlon1, K. Minnehan1, M. Gardel1, B. Pink1, L. York1, S. Sullivan1, R. Meyer1, B. Flaherty1, J. Christopher1, D. H. Wilson1, M.J. Conrad,2 P. Jarolim.2 1Quanterix Corporation, Lexington, MA, 2Brigham and Women’s Hospital, Harvard Medical School, Boston, MA.

Background: High-sensitivity cardiac troponin I (cTnI) measurement offers a promising new tool for early detection and monitoring of cardiovascular disease. The ability to reliably assign TnI values to all normal subjects tested represents a newly desired assay capability in many applications. We report preliminary analytical data from a prototype digital immunoassay for serum TnI that is capable of 2-3 logs greater sensitivity than the clinically used cTn assays and 1- 2 logs greater sensitivity than the latest high-sensitivity troponin assays, most of which are not yet commercially available.